Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 8/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4879253 | 0.80 | ALDH1A1 (0.66) | EPHX2ALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL19457351 | 0.77 | LMNA (0.69) | EPHX2ALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL4873753 | 0.77 | ALDH1A1 (0.61) | EPHX2ALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL751729 | 0.76 | ALDH1A1 (1.00) | ALDH1A1LMNAGAASMN1; SMN2NPC1 | |
| SCHEMBL4880869 | 0.76 | LMNA (0.61) | EPHX2ALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL4006920 | 0.75 | EPHX2 (0.77) | EPHX2ALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL4006917 | 0.75 | EPHX2 (0.77) | EPHX2ALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL4882655 | 0.75 | GAA (0.59) | EPHX2ALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL17875073 | 0.75 | LMNA (0.66) | EPHX2ALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL19011426 | 0.75 | LMNA (0.66) | EPHX2ALDH1A1LMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200467-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080200467-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080200467-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-21 | — | — | US | disclosed |
| WO-2008073623-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200467-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885ALDH1A1 519/4885LMNA 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.